Article

PRK okay for U.S. Army Special Forces using night vision goggles, study concludes

Washington, DC-PRK causes no loss of visual resolution and, in fact, improves uncorrected visual acuity (UCVA) and visual resolution during use of night vision goggles under a range of night sky conditions.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Part 6: Biggest innovations in ophthalmology in 50 years
Part 6: Biggest innovations in ophthalmology in 50 years
Part 5: Biggest innovations in ophthalmology in 50 years
Part 5: Biggest innovations in ophthalmology in 50 years
Part 4: Biggest innovations in ophthalmology in 50 years
Part 4: Biggest innovations in ophthalmology in 50 years
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
Part 3: Biggest innovations in ophthalmology in 50 years
Part 3: Biggest innovations in ophthalmology in 50 years
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
Setting the stage in LA: Neda Shamie, MD, on the 19th Annual Controversies in Modern Eye Care
Part 2: Biggest innovations in ophthalmology in 50 years
Part 2: Biggest innovations in ophthalmology in 50 years
Part 1: Biggest innovations in ophthalmology in 50 years
Part 1: Biggest innovations in ophthalmology in 50 years
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
Related Content
EMA application filed by Bayer to expand aflibercept 8mg indication to include retinal vein occlusion
April 9th 2025

EMA application filed by Bayer to expand aflibercept 8mg indication to include retinal vein occlusion

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

FDA accepts biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD
April 9th 2025

FDA accepts biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMD

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Tenpoint Therapeutics submits NDA application to FDA for BRIMOCHOL PF for the treatment of presbyopia
April 8th 2025

Tenpoint Therapeutics submits NDA application to FDA for BRIMOCHOL PF for the treatment of presbyopia

(Image courtesy of the Australian Society of Ophthalmologists)
April 8th 2025

Breaking barriers: Australian Society of Ophthalmologists’ first woman CEO steps up

© 2025 MJH Life Sciences

All rights reserved.